Abstract library

78 results for "injection device".
#215 Nurse Evaluation of Long-acting Somatostatin Analogue Injection Devices: A Quantitative Study
Introduction: The two major long-acting somatostatin analogues (SSA) available on the European market for the treatment of neuroendocrine tumors and acromegaly are Somatuline Autogel (SA) and Sandostatin LAR (LAR).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Hannah Kurth
#1646 Patient Satisfaction Regarding Home Injection Service for Somatostatin Analogues: A Survey Among Patients with a Neuroendocrine Tumour
Introduction: Depot somatostatin analogues (SSA) Sandostatin LAR® (SL) and Somatuline Autogel® (SA) injections, are facilitated by a professional home injection service.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Wanda Geilvoet
#1699 Should the Selective Arterial Secretagogue Injection Test for Insulinoma Localization be Evaluated at 60 Seconds or At 120 Seconds?
Introduction: The selective arterial secretagogue injection (SASI) test is considered indispensable for an accurate insulinoma localization. The optimal timing of post-injection evaluation has not been established yet, as some studies recommend 60 seconds [SASI (60 sec)] while others support 120 seconds [SASI (120 sec)].
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Keijiro Ueda
Authors: Ueda K, Kawabe K, Lee L, Tachibana Y, ...
#1708 STREET - Somatostatin Treatment Experience Trial
Introduction: Somatostatin analogs (SSA) delay progress and decrease symptoms in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs). It is not known whether patients’ experiences of injection treatment differ between different SSAs.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Ass. prof. Martin Almquist
#1759 Safety and Tolerability of "Ready-to-Use" (SOMAKIT TOC®) 68Ga-DOTA0-Tyr3-Octreotide (68Ga-DOTATOC) for Injection in Patients with Proven Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs)
Introduction: 68Ga-DOTATOC (PET) has superior diagnostic performance than Octreoscan (SPECT) in patients with GEP-NETs.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Angela Lamarca
Keywords: SomaKit, DOTATOC, GEP-NET
#2075 Phase 1 Pharmacokinetic and Pharmacodynamic Study of APOC, a New Controlled Release Formulation (CRF) of 15mg Octreotide Acetate in Healthy Male Volunteers
Introduction: Somatostatin analogues (SSAs) are considered the gold standard for systemic therapy of advanced neuroendocrine tumors (NETs). Octreotide is one of the SSAs most widely used in long-term therapies of NETs. There is increasing evidence that clinical benefits could be obtained with higher SSAs circulating levels but remain unreachable with current products without impacting significantly the quality of life of the patients. APOC is a new injectable controlled release technology containing Octreotide invented and developed by Ascil-Biopharm and designed to cover specifically these clinical unmet needs. It is presented as ready-to-use and can easily be manufactured at selected doses and durations in prefilled syringe.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Rosa Maria Antonijoan Arbós
#2837 Development and Initial Validation of a Brief Questionnaire to Assess Patient Satisfaction with Self-Injection of Lanreotide Autogel: Results During a Home Training Programme
Introduction: The long acting formulation of lanreotide autogel(LAN) can facilitate self-injection (SI) by patients or caregivers at home, avoiding visits to health centers. Training by nurses is required to ensure successful SI. Patient satisfaction(PS) is an important outcome of SI and home care programs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: MD PhD Jorge Hernando-Cubero
#2838 Accidental Injection of Unlabeled Lu-177 Caused Catastrophic Consequences in Patients with Neuroendocrine Tumor
Introduction: Since Lu-177 DOTATATE treatment is not approved in South Korea, patients with neuroendocrine tumors were sent to Germany and Malaysia for the treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Professor Keon Wook Kang
Authors: Kang K W, Song Y S, Kwon T E, Ha W H, ...
#3021 Homecare Service for Administration of Lanreotide Autogel Injections: Assessment of Patients’ Experience
Introduction: In the past, all Neuroendocrine Neoplasm (NEN) patients (pts) on long-acting somatostatin analogues (SA), had to attend local hospitals/clinics to have them administered by nurses/doctors. Recently, a “homecare service” was developed, allowing pts to have their injections delivered to their home and injections were either administered by themselves, their partner or a Specialist Nurse (SN).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Julian Gertner
Keywords: homecare
#1819 Initial Experience of a Novel Endoscopic Full Thickness Resection Device (FTRD) for the Treatment of Rectal Neuroendocrine Tumours
Introduction: Standard endoscopic resection of rectal NETs is often associated with histological incomplete excision due to submucosal position within the bowel. Endoscopic full thickness resection may allow early definitive management.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: PRRT-Ablative therapies- Endoscopic treatment, surgical treatment
Presenting Author: John Knight
Authors: Fong M, Ramsey E, Boger P, Ellis R, ...